Overview
- Daraxonrasib met all main goals Monday, extending median survival to 13.2 months versus 6.7 with chemotherapy and triggering early termination of the study.
- Following Monday’s readout, shares rose about 38% to 40% as the company said it will seek rapid FDA review using a Commissioner’s National Priority Voucher that shortens decision times to months.
- Key details, including how much benefit came from tumors with specific RAS variants such as G12, remain undisclosed and will be presented at upcoming scientific meetings.
- Revolution described a manageable safety profile, though patient accounts like Ben Sasse’s highlight severe rash and bleeding that clinicians may need to manage with dose holds and supportive care.
- The pill targets RAS mutations present in over 90% of pancreatic cancers, and additional Phase 3 trials in newly diagnosed pancreatic cancer and non‑small cell lung cancer are ongoing.